- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
Bayer Acquires Global AI Imaging Platform Company
Acquisition of Blackford Analysis is intended to advance Bayer’s position in digital medical imaging.
With a global medical imaging AI field with an estimated reach of $1.4B USD 2026, Bayer announced the acquisition of global imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow, with the goal to ultimately improve patient care and advance Bayer’s position in digital medical imaging. Bayer launched its own medical imaging platform, Calantic™ Digital Solutions in June 2022 based on technology from Blackford and a development and license agreement between both companies in 2020. Blackford will continue to operate as an independent organization after the acquisition is finalized.
Read more about the acquisition.
What Pharma Fears Most About AI
In this Q&A with Pharmaceutical Executive®, Andrew Hopkins, founder and CEO of Exscientia, reveals how artificial intelligence (AI) is currently being utilized in the pharma industry, predictions for where AI can be implemented in the future, and what pharma fears most about AI.
